Inventor
ANZALONE LUIGI
US26 patents
⚠️ This page may combine multiple inventors who share the name “ANZALONE LUIGI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ANZALONE LUIGI
6 patentsUS8710256B2Apr 29, 2014
Process for the preparation of protected L-alanine derivatives
ANZALONE LUIGI16 citations91
US8609865B2Dec 17, 2013
Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
ANZALONE LUIGI14 citations91
USD322947SJan 7, 1992
Sports car
ANZALONE LUIGI0 citations51
USD318444SJul 23, 1991
Automotive vehicle
ANZALONE LUIGI1 citations51
US8263785B2Sep 11, 2012
Process for the preparation of chymase modulators
ANZALONE LUIGI0 citations48
US8222431B2Jul 17, 2012
Process for synthesizing phosphonic and phosphinic acid compounds
ANZALONE LUIGI0 citations38
JANSSEN PHARMACEUTICA NV
4 patentsUS7994206B2Aug 9, 2011
Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
JANSSEN PHARMACEUTICA NV18 citations92
US9187408B2Nov 17, 2015
Process for the preparation of protected L-alanine derivatives
JANSSEN PHARMACEUTICA NV0 citations52
US8853445B2Oct 7, 2014
Process for the preparation of protected L-alanine derivatives
JANSSEN PHARMACEUTICA NV0 citations52
US8378122B2Feb 19, 2013
Process for the preparation of chymase modulators
JANSSEN PHARMACEUTICA NV0 citations48
DU PONT PHARM CO
4 patentsUS5932749AAug 3, 1999
Asymmetric synthesis of R-α-propyl-piperonyl amine and its analogs
DU PONT PHARM CO33 citations89
US6022977AFeb 8, 2000
Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
DU PONT PHARM CO2 citations61
US6194569B1Feb 27, 2001
Efficient process for the preparation of [S-(R,S)]-N-[1,3-benzodioxol-5-yl)butyl]-3,3-diethyl-2[4-[4-methyl-1-piperazinyl)carbonyl]phenoxy]-4-oxo-1-azetidine carboxamide, a human leukocyte elastase inhibitor
DU PONT PHARM CO3 citations59
US6218534B1Apr 17, 2001
Preparation of asymmetric cyclic ureas through a monoacylated diamine intermediate
DU PONT PHARM CO0 citations45
FURIEX PHARMACEUTICALS INC
3 patentsUS9115091B2Aug 25, 2015
Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
FURIEX PHARMACEUTICALS INC11 citations91
US8859604B2Oct 14, 2014
Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
FURIEX PHARMACEUTICALS INC14 citations91
US8691860B2Apr 8, 2014
Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
FURIEX PHARMACEUTICALS INC16 citations91
BRISTOL MYERS SQUIBB PHARMA CO
3 patentsUS6667332B2Dec 23, 2003
Efficient process for the preparation of a factor Xa inhibitor
BRISTOL MYERS SQUIBB PHARMA CO11 citations72
US6747158B2Jun 8, 2004
Efficient process for the preparation of a factor Xa inhibitor
BRISTOL MYERS SQUIBB PHARMA CO4 citations61
US6452000B2Sep 17, 2002
Preparation of asymmetric cyclic ureas through a monoacylated diamine intermediate
BRISTOL MYERS SQUIBB PHARMA CO1 citations45